SCHEMBL10217470

SCHEMBL10217470

COc1ccc(OC)c(COc2cc(-c3ccc(C(=O)N4CCC(N5CCCC5)CC4)cc3)cnc2N)c1

nearest known ligand 0.54

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ MET P08581 11/20 0.54
▸ MERTK Q12866 3/20 0.51
▸ AXL P30530 2/20 0.49
▸ TLR9 Q9NR96 1/20 0.48
▸ TLR8 Q9NR97 1/20 0.48
▸ TLR7 Q9NYK1 1/20 0.48
▸ MEN1 O00255 1/20 0.47
▸ KMT2A Q03164 1/20 0.47
▸ ATR Q13535 1/20 0.44
▸ NPC1 O15118 1/20 0.44
▸ MBTD1 Q05BQ5 1/20 0.43
▸ TP53BP1 Q12888 1/20 0.43
▸ L3MBTL4 Q8NA19 1/20 0.43
▸ L3MBTL3 Q96JM7 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ KCNH2 Q12809 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10217705 0.88 MET (0.56) METMERTKAXLATRMBTD1
SCHEMBL10217501 0.87 MERTK (0.58) METMERTKAXLMEN1KMT2A
SCHEMBL10217716 0.86 MET (0.54) METMERTKAXLMEN1KMT2A
SCHEMBL10217665 0.86 MET (0.54) METMERTKAXLTLR9TLR8
SCHEMBL10217476 0.85 MET (0.56) METMERTKAXLTLR9TLR8
SCHEMBL10217730 0.85 MET (0.51) METMERTKAXLATRL3MBTL3
SCHEMBL10217770 0.85 MET (0.59) METMERTKAXLMEN1KMT2A
SCHEMBL488733 0.84 MET (0.56) METMERTKAXLATRL3MBTL3
SCHEMBL30453025 0.84 MET (0.56) METMERTKAXLATRL3MBTL3
SCHEMBL10217398 0.84 MET (0.65) METMERTKAXLMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8106197-B2 Aminoheteroaryl compounds as protein kinase inhibitors PFIZER INC. (US) 2012-01-31 — — US disclosed
US-8106197-B2 Aminoheteroaryl compounds as protein kinase inhibitors PFIZER INC. (US) 2012-01-31 — — US disclosed
US-7230098-B2 2-amino- pyridines and pyrazines additionally substituted witn one or more carbocyclic or heterocyclic groups, e.g., 4-[6-amino-5-(2,6-dichloro-benzyloxy)-pyridin-3-yl]-phenol, for treating many kinds of cancer SUGEN, INC. (US) 2007-06-12 — — US disclosed
US-7230098-B2 2-amino- pyridines and pyrazines additionally substituted witn one or more carbocyclic or heterocyclic groups, e.g., 4-[6-amino-5-(2,6-dichloro-benzyloxy)-pyridin-3-yl]-phenol, for treating many kinds of cancer SUGEN, INC. (US) 2007-06-12 — — US disclosed
US-20070072874-A1 Aminoheteroaryl compounds as protein kinase inhibitors SUGEN, INC. 2007-03-29 — — US disclosed
US-20070072874-A1 Aminoheteroaryl compounds as protein kinase inhibitors SUGEN, INC. 2007-03-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070072874-A1 Aminoheteroaryl compounds as protein kinase inhibitors MET, MAP4K1, MAP4K2 MET 1/4885MERTK 69/4885AXL 623/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback